Find information on thousands of medical conditions and prescription drugs.

Lupron

Leuprolide is a gonadotropin-releasing hormone agonist (GnRH agonist). By causing constant stimulation of the pituitary GnRH receptors, it intially causes stimulation (flare), but thereafter decreases pituitary secretion (downregulation) of gonadotropins luteinizing hormone (LH) and follicle stimulating hormone (FSH). more...

Home
Diseases
Medicines
A
B
C
D
E
F
G
H
I
J
K
L
Labetalol
Lacrisert
Lactitol
Lactuca virosa
Lactulose
Lamictal
Lamisil
Lamivudine
Lamotrigine
Lanophyllin
Lansoprazole
Lantus
Lariam
Larotid
Lasix
Latanoprost
Lescol
Letrozole
Leucine
Leucovorin
Leukeran
Levaquin
Levetiracetam
Levitra
Levocabastine
Levocetirizine
Levodopa
Levofloxacin
Levomenol
Levomepromazine
Levonorgestrel
Levonorgestrel
Levophed
Levora
Levothyroxine sodium
Levoxyl
Levulan
Lexapro
Lexiva
Librium
Lidocaine
Lidopen
Linezolid
Liothyronine
Liothyronine Sodium
Lipidil
Lipitor
Lisinopril
Lithane
Lithobid
Lithonate
Lithostat
Lithotabs
Livostin
Lodine
Loestrin
Lomotil
Loperamide
Lopressor
Loracarbef
Loratadine
Loratadine
Lorazepam
Lortab
Losartan
Lotensin
Lotrel
Lotronex
Lotusate
Lovastatin
Lovenox
Loxapine
LSD
Ludiomil
Lufenuron
Lupron
Lutropin alfa
Luvox
Luxiq
Theophylline
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z

Like other GnRH agonists, leuprolide may be used in the treatment of hormone-responsive cancers such as prostate cancer or breast cancer, estrogen-dependent conditions (such as endometriosis or uterine fibroids), to treat precocious puberty, and to control ovarian stimulation in IVF.

Leuprolide acetate is marketed by Bayer AG under the brand name Viadur, by Sanofi-Aventis under the brand name Eligard, and by TAP Pharmaceuticals under the brand name Lupron.

Read more at Wikipedia.org


[List your site here Free!]


Tap pharmaceuticals will pay $875 million in lupron case - Pharmacy Watch - Brief Article
From Drug Store News, 11/19/01

Tap Pharmaceuticals pleaded guilty to criminal misconduct charges in a Boston federal court Oct. 16 in one of the biggest health care fraud cases in U.S. history.

Tap, a joint venture of Abbott Laboratories and Takeda Chemical Industries, will pay up to $875 million in criminal and civil damages for questionable sales and marketing practices involving Lupron (leuprolide acetate), a drug used to treat prostate cancer and other diseases. The U.S. District Attorney in Massachusetts, who prosecuted the case, charged Tap with providing "free samples" of Lupron to doctors and then helping them get Medicare and Medicaid to pay for them. They also were accused of inflating the average wholesale price of the drug and conducting a lucrative series of kick-backs with doctors who prescribed Lupron instead of its competitor, AstraZeneca's Zoladex (goserelin acetate implant). The investigation, according to published reports, began years prior when Tap sales representatives offered a Massachusetts urologist $65,000 to authorize the Lupron treatment for his HMO instead of Zoladex. The urologist, the HMO and a former vice president of sales for Tap now share a $95 million dollar whis tle-blower award as part of the settlement.

Bristol-Myers Squibb and Schering-Plough still are under investigation by the same Massachusetts authorities for similar sales and marketing allegations. In a prepared statement, Abbott noted that its reserves "are adequate to cover its half" of the settlement.

COPYRIGHT 2001 Reproduced with permission of the copyright holder. Further reproduction or distribution is prohibited without permission.
COPYRIGHT 2001 Gale Group

Return to Lupron
Home Contact Resources Exchange Links ebay